Recent News

• 06.10.2025 - Enveric Biosciences Receives Notice of Allowance for New Class of Low-Hallucinogenic Neuroplastogens Targeting Psychiatric Disorders
• 06.03.2025 - Enveric’s Patent Win Targets New Frontiers in Sleep Medicine [Microdose]
• 06.03.2025 - Enveric Biosciences Announces Issuance of U.S. Patent Covering a Novel Family of Molecules Including Melatonin Receptor-Targeting Compounds
• 05.28.2025 - Enveric Biosciences Reports Positive Preclinical Results for Lead Drug Candidate EB-003
• 05.20.2025 - Enveric Biosciences Identifies Neuroplastogen Candidates with Potential to Address Neurodegenerative Disease
• 05.14.2025 - Enveric Biosciences Reports First Quarter 2025 Financial and Corporate Results

Recent Filings

• 06.03.2025 - 8-K Current report
• 05.14.2025 - EX-99.1 EX-99.1
• 05.14.2025 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 05.14.2025 - 8-K Current report
• 05.12.2025 - 4 Statement of changes in beneficial ownership of securities
• 05.12.2025 - 4 Statement of changes in beneficial ownership of securities
• 05.12.2025 - 4 Statement of changes in beneficial ownership of securities
• 04.17.2025 - EFFECT Notice of Effectiveness
• 04.16.2025 - ARS Annual Report to Security Holders
• 04.16.2025 - CORRESP Correspondence